Intervention Protocol

You have free access to this content

Rituximab for treating inhibitors in children with hemophilia

  1. Yi Liu1,2,3,
  2. Lingli Zhang1,2,*,
  3. Cristina Santoro4,
  4. Jie Song1,2,3,
  5. Armando Rodriguez5,
  6. Li Wang6

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 30 OCT 2013

Assessed as up-to-date: 23 OCT 2013

DOI: 10.1002/14651858.CD010810


How to Cite

Liu Y, Zhang L, Santoro C, Song J, Rodriguez A, Wang L. Rituximab for treating inhibitors in children with hemophilia (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010810. DOI: 10.1002/14651858.CD010810.

Author Information

  1. 1

    West China Second University Hospital, Sichuan University, Department of Pharmacy, Evidence-based Pharmacy Center, Chengdu, Sichuan, China

  2. 2

    Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Chengdu, China

  3. 3

    Sichuan University, West China Second University Hospital, Chengdu, China

  4. 4

    Sapienza University of Rome, Department of Hematology and Cellular Biotechnology, Rome, Italy

  5. 5

    Association for the Promotion of Multimedia Education, Zagreb, Croatia

  6. 6

    West China Hospital, Sichuan University, Chinese Cochrane Centre, Chengdu, Sichuan, China

*Lingli Zhang, zhlingli@sina.com.

Publication History

  1. Publication Status: New
  2. Published Online: 30 OCT 2013

SEARCH

References

Additional references

Borker 2011
  • Borker A, Choudhary N. Rituximab. Indian Pediatrics 2011;48(8):627-32.
Collins 2009
Coppola 2012
  • Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Seminars in Thrombosis and Hemostasis 2012;38(1):79-94.
DiMichele 2007
Egger 1997
  • Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
FDA 2013
  • Food, Drug Administration. Highlights of Prescribing Information (Rituxan). Food and Drug Administration.http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103705s5409lbl.pdf (accessed 21 Augest 2013).
Franchini 2008
Giulino 2007
  • Giulino LB,  Bussel JB,  Neufeld EJ,  Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network. Treatment with rituximab in benign and malignant hematologic disorders in children. Journal of Pediatrics 2007;150(4):338-44, 344, e1.
Gouw 2007a
  • Gouw SC,  van der Bom JG,  Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109(11):4648-54.
Gouw 2007b
  • Gouw SC,  van der Bom JG,  Auerswald G,  Ettinghausen CE,  Tedgård U,  van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 1 June 2007 (accessed in 19 Augest 2013);109(11):4693-7.
Gouw 2013a
  • Gouw SC,  van den Berg HM,  Fischer K,  Auerswald G,  Carcao M, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013;121(20):4046-55.
Gouw 2013b
  • Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, et al. Factor VIII products and inhibitor development in severe hemophilia A. New England Journal of Medicine 2013;368(3):231-39.
Grace 2012
Hay 2012
  • Hay CR, DiMichele DM, on behalf of the International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012;119(6):1335-44.
Higgins 2011a
  • Higgins JPT, Altman DG, Sterne JAC, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Higgins 2011b
  • Higgins JPT, Deeks JJ, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Iorio 2010a
  • Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis 2010;8(6):1256-65.
Iorio 2010b
Iorio 2011
Kavcic 2013
  • Kavcic M, Fisher BT, Seif AE, Li Y, Huang YS, Walker D, et al. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. Journal of Pediatrics 2013;162(6):1252-8.
Kuzmanovic 2012
  • Kuzmanovic M, Jurisic V. Rituximab for treatment of autoimmune hemolytic anemia. Indian Pediatrics 2012;49(8):672-4.
Leissinger 2011
  • Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. New England Journal of Medicine 2011;365(18):1684-92.
NHLBI 2011
  • U.S. National Heart Lung and Blood Institute. What is hemophilia?. http://www.nhlbi.nih.gov/health/health-topics/topics/hemophilia/ (accessed 18 November 2012).
Nwobi 2008
Pescovitz 2006
RevMan 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Selewski 2010
Stedman 2011
  • Stedman MR,  Curtin F,  Elbourne DR,  Kesselheim AS,  Brookhart MA. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2011;40(6):1732-4.
Verbruggen 1995
  • Verbruggen B,  Novakova I,  Wessels H,  Boezeman J,  van den Berg M,  et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thrombosis and Haemostasis 1995;73(2):247-51.
WFH 2012a
  • World Federation of Hemophilia. About bleeding disorders-How are inhibitors diagnosed?. World Federation of Hemophilia. http://www.wfh.org/en/page.aspx?pid=648 (accessed 18 November 2012).
WFH 2012b
  • World Federation of Hemophilia. About bleeding disorders-Who is at risk of developing inhibitors?. World Federation of Hemophilia http://www.wfh.org/en/page.aspx?pid=653 (accessed in 19 Augest 2013).
WFH 2012c
  • World Federation of Hemophilia. About bleeding disorders, what is hemophilia?. http://www.wfh.org/en/page.aspx?pid=646 (accessed 18 November 2012).
WFH 2013
  • World Federation of Hemophilia. About bleeding disorders-What are inhibitors?. World Federation of Hemophilia.http://www.wfh.org/en/page.aspx?pid=651 (Accessed 19 August 2013).
Yadav 2012